Managing HCV Infection and Adherence in the Direct-Acting Antiviral Era: Learning from the HIV Experience

Vincent Lo Re, MD, MSCE
Division of Infectious Diseases
Center for Clinical Epidemiology and Biostatistics
Perelman School of Medicine
University of Pennsylvania
Disclosures

• Research grant support from:
  – National Institute of Allergy and Infectious Diseases
  – Agency for Healthcare Research and Quality
  – Department of Veterans Affairs
  – AstraZeneca
  – Bristol-Myers Squibb
  – Gilead Sciences
Outline

• Challenges in HCV therapy
• Adherence: HCV response relationship
• Changes in antiviral adherence over time
• Barriers to adherence to HCV therapy
• Implications / future directions
Outline

• Challenges in HCV therapy
• Adherence : HCV response relationship
• Changes in antiviral adherence over time
• Barriers to adherence to HCV therapy
• Implications / future directions
Case: 54 yo African-American Woman with HIV and HCV Infection

- **HIV (11/2004):**
  - ART: LPV/RTV, ZDV/LMV
  - 6/2011: CD4+ 354/mm$^3$ (22%); HIV <75 c/mL

- **Chronic HCV (12/2004):**
  - HCV genotype 1; HCV RNA=6.1 log IU/mL

- **Past Hx:** diabetes, depression

- **Meds:** LPV/RTV, ZDV/LMV, metformin

- **Social Hx:** IV heroin (1996-2004); no EtOH
Case: 54 yo African-American Woman with HIV and HCV Infection

- Exam: No hepatomegaly, stigmata of ESLD
- Laboratory data:
  - TB 0.8; Alb 3.8; INR 1.1; ALT 113
  - WBC 6.3; Hgb 14.9; platelets 138
- HCV Fibrosure=0.84 → cirrhosis
- Interleukin-28b: C/T genotype
- Abdominal U/S: No liver masses or ascites
Case: 54 yo African-American Woman with HIV and HCV Infection

- Changed ART regimen:
  - Raltegravir, tenofovir, emtricitabine
  - 4 wks later: tolerating ART; HIV <75 copies/mL

- Initiated HCV therapy
  - Peg-IFN alfa-2a 180 mcg/wk
  - Ribavirin 600 mg twice daily
  - Telaprevir 750 mg every 8 hrs
Case: 54 yo African-American Woman with HIV and HCV Infection

- Week 4 of HCV therapy:
  - Flu-like symptoms, controlled (ibuprofen)
  - Evaluation:
    - WBC 2.8 (ANC 1,020); Hgb 13.4; Plt 112
    - ALT 68
    - HCV RNA 2.1 log IU/mL (↓ 4.0 log IU/mL)
Case: 54 yo African-American Woman with HIV and HCV Infection

• Week 12 of HCV therapy:
  – ↓ flu-like symptoms, no mood changes
  – Evaluation:
    • WBC 2.1 (ANC 860); Hgb 9.4; Plt 94
    • ALT 41
    • HCV RNA undetectable
  – Anemia management:
    • Initiated erythropoetin 40,000 units/wk
    • ↓ ribavirin to 1,000 mg/d
Case: 54 yo African-American Woman with HIV and HCV Infection

- Week 24 of HCV therapy:
  - Fatigue; irritability; missing ribavirin doses
- Evaluation:
  - WBC 2.3 (ANC 940); Hgb 11.8; Plt 80
  - HIV < 75 copies/mL
  - ALT 64
  - HCV RNA 2.6 log IU/mL
Case: 54 yo African-American Woman with HIV and HCV Infection

- Week 24 of HCV therapy:
  - Fatigue; irritability; missing ribavirin doses
- Evaluation:
  - WBC 2.3 (ANC 940); Hgb 11.8; Plt 80
  - HIV < 75 copies/mL
  - ALT 64
  - HCV RNA 2.6 log IU/mL

Detectable, Therapy Stopped
Possible Reasons for HCV Treatment Failure

- **Host Factors**
  - Adherence
  - Advanced fibrosis
  - Black race
  - Insulin resistance

- **Genetics**
  - Interleukin-28B

- **Viral Factors**
  - Genotype 1
  - \(\uparrow\) HCV RNA
  - HIV coinfection

HCV Treatment Failure
## HCV Treatment Regimens With HIV Coinfection (2012)

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Therapeutic Options</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PEG-IFN-2b + ribavirin + boceprevir⁰</td>
<td>48 wks</td>
</tr>
<tr>
<td></td>
<td>PEG-IFN-2a + ribavirin + telaprevir⁰</td>
<td>48 wks</td>
</tr>
<tr>
<td>2, 3</td>
<td>PEG-IFN-2a or -2b + ribavirin</td>
<td>48 wks</td>
</tr>
<tr>
<td>4</td>
<td>PEG-IFN-2a or -2b + ribavirin</td>
<td>48 wks</td>
</tr>
<tr>
<td></td>
<td>PEG-IFN + ribavirin + nitazoxanide⁰</td>
<td>48 wks</td>
</tr>
</tbody>
</table>

⁰ Off-label usage; no response-guided therapy in HIV/HCV patients.

Sustained virologic response (SVR) = HCV RNA (−) ≥24 wks after end of therapy
PEG-Interferon + Ribavirin

• Pegylated interferon alfa
  – Suppress viral replication
  – Two formulations: 2a, 2b
    • Alfa-2a: 180 mcg/wk SQ
    • Alfa-2b: 1.5 mcg/kg/wk SQ

• Ribavirin
  – Nucleoside analogue
  – Genotype 1, 4:
    • ≤75 kg: 1,000 mg/d
    • >75 kg: 1,200 mg/d
  – Genotype 2, 3: 800 mg/d
Boceprevir: HCV Genotype 1

- NS3/4A protease inhibitor
- Indicated for genotype 1 only
- Use with PEG-IFN + ribavirin

- Dosage: 800 mg every 8 hrs
- Metabolized via CYP3A4/5, aldoketoreductase

If HCV RNA >100 IU/mL at Wk 12, stop therapy

Telaprevir: HCV Genotype 1

- **NS3/4A protease inhibitor**
- **Indicated for genotype 1 only**
- **Use with PEG-IFN + ribavirin:**
  - **Dosage:** 750 mg every 8 hrs
  - **Administer with 20 gm fat meal**
  - **Metabolized via CYP3A4/5**

**PEG + RBV**

- **Week 12**
- **Week 48**
- **Total 48 wks**

*If HCV RNA >1,000 IU/mL at Wk 4 or 12, stop therapy*

SVR12 Rates with Boceprevir for HCV Genotype 1 in HIV

SVR12 = Undetectable HCV RNA 12 weeks after treatment cessation

Sulkowski MS et al. 19th CROI. Abstract 47.
SVR12 Rates with Telaprevir for HCV Genotype 1 in HIV

Dieterich D et al. 19th CROI. Abstract 46.

SVR12 = Undetectable HCV RNA 12 weeks after treatment cessation
Toxicities of HCV Therapy

• Tend to dominate treatment of HCV
• Adverse events affect:
  – Quality of life
  – Follow-up
  – Adherence to antiviral therapy
# Notable Toxicities of PEG-IFN / Ribavirin in HIV Trials

## Pegylated Interferon

<table>
<thead>
<tr>
<th>Adverse Effect</th>
<th>% Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>44%</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>44%</td>
</tr>
<tr>
<td>Myalgia</td>
<td>36%</td>
</tr>
<tr>
<td>Depression</td>
<td>29%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>26%</td>
</tr>
<tr>
<td>Thyroid dysfunction</td>
<td>6%</td>
</tr>
</tbody>
</table>

## Ribavirin

<table>
<thead>
<tr>
<th>Adverse Effect</th>
<th>% Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemolytic anemia</td>
<td>16%</td>
</tr>
</tbody>
</table>
## Notable Toxicities of Boceprevir / Telaprevir in HIV Trials

<table>
<thead>
<tr>
<th></th>
<th>BOC+P/R (N=64)</th>
<th>P/R (N=34)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anemia</strong></td>
<td>41%</td>
<td>26%</td>
</tr>
<tr>
<td><strong>Pyrexia</strong></td>
<td>36%</td>
<td>21%</td>
</tr>
<tr>
<td><strong>Asthenia</strong></td>
<td>34%</td>
<td>24%</td>
</tr>
<tr>
<td><strong>Anorexia</strong></td>
<td>34%</td>
<td>18%</td>
</tr>
<tr>
<td><strong>Diarrhea</strong></td>
<td>28%</td>
<td>18%</td>
</tr>
<tr>
<td><strong>Dysgeusia</strong></td>
<td>28%</td>
<td>15%</td>
</tr>
<tr>
<td><strong>Vomiting</strong></td>
<td>28%</td>
<td>15%</td>
</tr>
<tr>
<td><strong>Flu-like illness</strong></td>
<td>25%</td>
<td>38%</td>
</tr>
<tr>
<td><strong>Neutropenia</strong></td>
<td>19%</td>
<td>6%</td>
</tr>
<tr>
<td><strong>Erythropoietin use</strong></td>
<td>38%</td>
<td>21%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>TVR+P/R (N=38)</th>
<th>P/R (N=22)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pruritus</strong></td>
<td>39%</td>
<td>9%</td>
</tr>
<tr>
<td><strong>Headache</strong></td>
<td>37%</td>
<td>27%</td>
</tr>
<tr>
<td><strong>Nausea</strong></td>
<td>3%</td>
<td>23%</td>
</tr>
<tr>
<td><strong>Rash</strong></td>
<td>34%</td>
<td>23%</td>
</tr>
<tr>
<td><strong>Pyrexia</strong></td>
<td>21%</td>
<td>9%</td>
</tr>
<tr>
<td><strong>Depression</strong></td>
<td>21%</td>
<td>9%</td>
</tr>
<tr>
<td><strong>Neutropenia</strong></td>
<td>24%</td>
<td>23%</td>
</tr>
<tr>
<td><strong>Anemia</strong></td>
<td>18%</td>
<td>18%</td>
</tr>
<tr>
<td><strong>Insomnia</strong></td>
<td>13%</td>
<td>23%</td>
</tr>
<tr>
<td><strong>Anorexia</strong></td>
<td>11%</td>
<td>18%</td>
</tr>
</tbody>
</table>

---

1. Sulkowski MS et al. 19th CROI. Abstract 47.
Challenges in HCV Therapy

- Complex treatment regimen
- Frequent monitoring of laboratory results
- Office visits to evaluate adverse effects
- Toxicities of HCV treatment
- May need to change ART regimen
- Suboptimal adherence $\rightarrow \downarrow$ response
Adherence to HCV Therapy

• Prior data:
  – ↓ drug exposure from dose reduction: ↓ SVR
  – Few data: ↓ drug exposure from missed doses

• Unanswered questions:
  – Levels of adherence for virologic response
  – Differences between PEG-IFN, ribavirin
  – Changes in antiviral adherence over time
  – Risk factors for non-adherence

Outline

- Challenges in HCV therapy
- Adherence: HCV response relationship
- Changes in antiviral adherence over time
- Barriers to adherence to HCV therapy
- Implications / future directions
Learning from the HIV Experience: ART Adherence and HIV Response

ART Adherence: ↓ in HIV RNA

ART Adherence: HIV Suppression

Study 1: Adherence and HCV Suppression

- **Aim:** Evaluate relation between adherence to PEG-IFN + ribavirin and HCV suppression over initial 12 weeks of HCV therapy
  - **Adherence:** Pharmacy refill measure
  - **Hypothesis:** ↑ adherence → Greater decline in HCV RNA

Study Design / Setting

- Design: Retrospective cohort study
- Setting: Philadelphia VA Med Center
  - Majority of veterans receive meds through VA*
  - PEG-IFN + ribavirin dispensed monthly
  - Patients must initiate contact to obtain refills
  - Dispensing of antivirals not linked
  - Prescribing info recorded in database

*Steiner JF et al. Med Care 1988;26:814-23.
Study Subjects

- **Eligibility criteria:**
  - HCV RNA+
  - Received at least one pharmacy refill of both PEG-IFN and ribavirin
  - HCV RNA prior to treatment and at 12 weeks

- **Exclusion:**
  - Started rx outside VA, switched formulation

- **Identification (VA pharmacy database):**
  - Prescribed PEG-IFN + ribavirin, 1/1/01–12/31/07
Adherence: Pharmacy Refills

- Compares actual versus expected refills
- Valid indicator of actual adherence
- Advantages:
  - Relatively simple to collect
  - Does not require patient recall
  - Permits determination of PEG-IFN and ribavirin adherence separately

Data Analysis: Calculation of Adherence

Fill #: 1st Fill | 2nd Fill | 3rd Fill | 4th Fill
---|---|---|---
Days: (Day 0) | (Day 32) | (Day 64) | (Day 98)

Days’ Supply: 30 days | 30 days | 30 days

Days’ Supply over 12 weeks

% Adherence = \frac{\text{Days’ Supply between 1st & Final Fills}}{\text{Days’ Supply over 12 weeks}} \times 100

% Adherence = \frac{90 \text{ days}}{98 \text{ days}} = 92\%
Main Study Outcome

• Decline in HCV RNA (log IU/mL) from baseline at 12 weeks
  – Week 12 RNA: Obtained weeks 11 – 13
Data Collection / Analysis

- Data abstracted from VA medical records
  - Baseline: closest to, prior to start of therapy
    - Demographic: age, sex, race, weight, height
    - Laboratory: HCV genotype / viral load, HIV, HBV
    - Pharmacy: fill dates, # dispensed, frequency, dose
  - Longitudinal: antiviral rxs, dose, week 12 RNA

- Mixed effects regression model:
  - Adherence and ↓ in HCV viral load
## Results: Patient Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All Subjects (N=188)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (yrs, IQR)</td>
<td>52 (48-56)</td>
</tr>
<tr>
<td>Male sex (no., %)</td>
<td>181 (96%)</td>
</tr>
<tr>
<td>Black race (no., %)</td>
<td>91 (48%)</td>
</tr>
<tr>
<td>Injection drug use (no., %)</td>
<td>124 (66%)</td>
</tr>
<tr>
<td>HCV viral load &gt;800,000 IU/mL (no., %)</td>
<td>107 (57%)</td>
</tr>
<tr>
<td>HCV genotype 1 or 4 (no., %)</td>
<td>152 (81%)</td>
</tr>
<tr>
<td>HIV coinfection (no., %)</td>
<td>15 (8%)</td>
</tr>
</tbody>
</table>
Results: Medication Dosing

PEG-Interferon

- 135 (72%) treated with PEG-IFN alfa-2a
  - 133 (99%) started at / maintained 180 μg/week
- 53 (28%) treated with PEG-IFN alfa-2b
  - 38 (72%) started on / maintained at least 1.4 μg/kg/wk

Ribavirin

- Genotype 1/4: 7 (5%) sub-optimal ribavirin dose
  - Week 12: 9 had ↓ ribavirin dose
- Genotype 2/3: 0 sub-optimal ribavirin dose
Results: Medication Dosing

PEG-Interferon

- 135 (72%) treated with PEG-IFN alfa-2a
  - 133 (99%) started at / maintained 180 ug/week
- 53 (28%) treated with PEG-IFN alfa-2b
  - 38 (72%) started on / maintained at least 1.4 μg/kg/wk

Ribavirin

- Genotype 1/4: 7 (5%) reduced ribavirin dose
  - Week 12: 9 had ↓ ribavirin dose
- Genotype 2/3: 0 reduced ribavirin dose
## Results: HCV Viral Load Decline in Good Vs. Poor Adherers

<table>
<thead>
<tr>
<th>Population</th>
<th>12-Week Adherence</th>
<th>HCV Decline</th>
<th>Difference</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All patients</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;85%</td>
<td></td>
<td>2.57</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥85%</td>
<td></td>
<td>3.23</td>
<td>0.66</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>Genotype 1 or 4</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;85%</td>
<td></td>
<td>2.28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥85%</td>
<td></td>
<td>2.95</td>
<td>0.67</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>Baseline HCV RNA &gt;800,000 IU/mL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;85%</td>
<td></td>
<td>2.77</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 85%</td>
<td></td>
<td>3.45</td>
<td>0.68</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>Baseline HCV RNA ≤800,000 IU/mL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;85%</td>
<td></td>
<td>2.26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥85%</td>
<td></td>
<td>2.95</td>
<td>0.69</td>
<td>0.1</td>
</tr>
</tbody>
</table>
Results: Exclusion of Subjects With Reduced Doses

- **16 subjects with reduced ribavirin doses:**
  - Overall:
    - ↓ in HCV RNA: 1.0 log IU/mL > for good adherers (p=0.01)
  - Genotypes 1 / 4:
    - ↓ in viral load: 1.09 log IU/mL > for good adherers (p=0.01)

- **17 subjects with reduced PEG-IFN doses:**
  - Differences in viral load ↓ between good and poor adherers similar to those with full PEG-IFN dose
Study 2: Adherence and HCV Response

- **Aim**: Evaluate relation between adherence to PEG-IFN, ribavirin and virologic response
  - Hypothesis: \( \uparrow \) adherence \( \rightarrow \) \( \uparrow \) HCV response

Study Design / Setting

- Retrospective cohort study
- Setting: U.S. VA Hepatitis C Case Registry
  - Extract of VA records from HCV+ veterans
  - Demographic, administrative, lab data
  - Dispensing data on meds
  - Advantages:
    - Majority receive meds through VA*
    - Initiate contact for refills (not automatic)
    - Dispensing of antivirals not linked

*Steiner JF et al. Med Care 1988;26:814-23.
Study Subjects

• Inclusion criteria:
  – HCV RNA+, HCV genotype 1 – 4
  – PEG-IFN + ribavirin rx: Jan 2003 → Dec 2006
  – HCV RNA prior to, after treatment start

• Exclusion criteria:
  – Clinical trial, switched IFN formulation, HIV

• Selection: first treatment course
Adherence: Pharmacy Refills

- Calculated over 12-wk intervals:
  - 0 – 12 wks
  - 13 – 24 wks
  - 25 – 36 wks
  - 37 – 48 wks
- Initial fills: closest to wks 13, 25, 37
- Included in analyses: fill during interval
- Observed fills analyzed in each interval
Study Outcomes

• **Early virologic response (EVR)**
  – $\geq 2\ \log\downarrow$ in HCV RNA copies/ml at 12 wks
  – Defined wk 12 HCV RNA: wks 9 – 15

• **Sustained virologic response (SVR)**
  – Undetectable HCV RNA in all follow-up viral load tests 24 wks after treatment end date
  – Collected HCV RNA → Dec. 2008
Data Analysis

• Calculated adherence separately

• Adherence categorized into 7 strata
  – Examined virologic response in each stratum
  – Chi-square tests for trend
Results: Subject Selection

9,468 HCV genotype 1 - 4
Prescribed PEG-IFN + Ribavirin

3,762 Excluded:
- 3,416 No HCV RNA prior to, after start of therapy
- 48 Received antivirals in clinical trial
- 75 Switched IFN formulation
- 205 HIV-infected
- 18 Infected with genotype 5 or 6

5,706 Patients Included

3,992 Available for EVR Analyses
### Results: Patient Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (yrs, SD)</td>
<td>52 (6)</td>
</tr>
<tr>
<td>Male sex (no., %)</td>
<td>5,482 (96%)</td>
</tr>
<tr>
<td>Race (no., %)</td>
<td></td>
</tr>
<tr>
<td>African-American</td>
<td>1,080 (19%)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>3,397 (60%)</td>
</tr>
<tr>
<td>HCV genotype 1 or 4 (no., %)</td>
<td>4,207 (74%)</td>
</tr>
<tr>
<td>HCV viral load &gt;400,000 IU/mL (no., %)</td>
<td>3,158 (55%)</td>
</tr>
</tbody>
</table>
Potential Limitations

- **Overestimate actual adherence**
  - Patients may not take meds after refill
    - Assoc. with biological surrogate that only responds to antiviral therapy

- **Retrospective design**
  - No standardized HCV RNA testing

- **Generalizability**
Conclusions

- ≥85% adherence associated with ↑ HCV viral suppression over initial 12 weeks
  - Viral load ↓ greater with optimal ribavirin dose
- ↑ EVR and SVR with higher levels of adherence to PEG-IFN and ribavirin
Outline

• Challenges in HCV therapy
• Adherence : HCV response relationship
• Changes in antiviral adherence over time
• Barriers to adherence to HCV therapy
• Implications / future directions
Learning from the HIV Experience: Change in Adherence Over Time

ART Adherence Over Time, MACS and WIHS

ART Adherence Over Time, HIV Epidemiology Research Study

Adherence Over Time: HCV-Monoinfected

<table>
<thead>
<tr>
<th>Adherence Interval (Weeks)</th>
<th>N</th>
<th>Mean PEG-Interferon Adherence (%, SD)</th>
<th>N</th>
<th>Mean Ribavirin Adherence (%, SD)</th>
<th>P-Value‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-12</td>
<td>5,706</td>
<td>100% (23%)</td>
<td>5,706</td>
<td>97% (38%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>13-24</td>
<td>3,542</td>
<td>95% (23%)</td>
<td>3,497</td>
<td>86% (38%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>25-36</td>
<td>2,501</td>
<td>94% (24%)</td>
<td>2,453</td>
<td>84% (38%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>37-48</td>
<td>904</td>
<td>89% (30%)</td>
<td>860</td>
<td>76% (40%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Mean ↓: 3.5% / 12 wks Mean ↓: 6.8% / 12 wks

p<0.001

‡ P-values via paired t-tests

# Adherence Over Time: HIV/HCV-Coinfected

<table>
<thead>
<tr>
<th>Adherence Interval (Weeks)</th>
<th>Mean PEG-Interferon Adherence (%)</th>
<th>Mean Ribavirin Adherence (%)</th>
<th>P-Value‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-12</td>
<td>99% (27%)</td>
<td>93% (38%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>13-24</td>
<td>96% (23%)</td>
<td>87% (38%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>25-36</td>
<td>100% (24%)</td>
<td>89% (38%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>37-48</td>
<td>88% (30%)</td>
<td>78% (40%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Mean ↓: 2.5% / 12 wks  Mean ↓: 4.1% / 12 wks  p<0.001

‡ P-values via paired t-tests
Conclusions

• Within person, differing antiviral adherence
  – PEG-IFN adherence higher than ribavirin
  – HIV: differing adherence to ARVs reported*

• Adherence to anti-HCV drugs ↓ over time
  – More so for ribavirin than PEG-IFN

Hypotheses

• **Possible reasons for ↓ ribavirin adherence:**
  – Fatigue, loss of concentration common
  – ↑ frequency of ribavirin administration may make it more vulnerable to missed doses

• **PEG-IFN:**
  – Patient select day of week to inject
  – Scheduling routine may promote ↑ adherence
Outline

• Challenges in HCV therapy
• Adherence : HCV response relationship
• Changes in antiviral adherence over time
• Barriers to adherence to HCV therapy
• Implications / future directions
Learning from the HIV Experience: Risk Factors for Non-Adherence

Demographic
- ↓ Age
- Education
- Black race

Psychosocial
- Depression
- ↓ Literacy
- ↓ Social support
- Chaotic lifestyle

Regimen
- # pills
- AEs
- Frequency

HIV Treatment Adherence
## Determinants of HCV Adherence: HCV-Monoinfected

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Mean Ribavirin Adherence Percent (95% CI)</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>With Factor</td>
<td>Without Factor</td>
</tr>
<tr>
<td>Depression</td>
<td>90.1%</td>
<td>90.1%</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>89.9%</td>
<td>90.1%</td>
</tr>
<tr>
<td>Methadone</td>
<td>88.9%</td>
<td>90.2%</td>
</tr>
<tr>
<td>New thyroid med</td>
<td>91.9%</td>
<td>89.9%</td>
</tr>
<tr>
<td>New growth factor</td>
<td>91.0%</td>
<td>89.7%</td>
</tr>
</tbody>
</table>

### Determinants of HCV Adherence: HIV/HCV-Coinfected

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Mean Ribavirin Adherence Percent (95% CI)</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>With Factor</td>
<td>Without Factor</td>
</tr>
<tr>
<td>Depression</td>
<td>87.3%</td>
<td>89.2%</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>90.2%</td>
<td>88.4%</td>
</tr>
<tr>
<td><strong>Methadone</strong></td>
<td>76.7%</td>
<td>89.4%</td>
</tr>
<tr>
<td>New thyroid med</td>
<td>94.9%</td>
<td>88.4%</td>
</tr>
<tr>
<td><strong>New growth factor</strong></td>
<td>97.7%</td>
<td>84.8%</td>
</tr>
</tbody>
</table>
Conclusions

• Patients prescribed growth factors had higher mean adherence to both antivirals

• Methadone use associated with lower mean adherence to PEG-IFN, ribavirin in HIV/HCV-coinfected
Hypotheses

• Growth factors to manage side effects
  – Relieve toxicities, ↑ adherence
  – Require more frequent visits, ↑ attention from clinical care team

• Methadone use in HIV/HCV
  – Cognitive dysfunction, ↓ adherence
Outline

• Challenges in HCV therapy
• Adherence : HCV response relationship
• Changes in antiviral adherence over time
• Barriers to adherence to HCV therapy
• Implications / future directions
Implications

- Adherence is key to effective HCV therapy
- Emphasize adherence throughout course
  - Adherence to anti-HCV drugs ↓ over time
- Addition of direct-acting antivirals:
  - ↑ complexity of HCV therapy
  - Might affect HCV treatment adherence
Integrating Hepatitis C Care into HIV Practice

- Establish multidisciplinary management team
- Provide support and education
- Treat psychiatric disorders / substance abuse
  - Administer CES-D and AUDIT
- Provide anti-HCV therapy
- Education to prepare for HCV therapy
- Offer weekly HCV adherence visits, monitoring

Future Directions in HCV Treatment Adherence

• Conceptual model: barriers to adherence
• Evaluate adherence to direct-acting antivirals
  – Adherence : response relationship
  – Differences in adherence to regimens, ART
  – Adherence $\rightarrow$ antiviral resistance
• Methods to measure adherence in real time
  – Identify non-adherence as soon as it occurs
• Develop adherence interventions
  – Modify successful HIV adherence interventions
"Arriving at meaningful solutions is an inevitably slow and difficult process. Nonetheless, better is possible. It does not take genius. It takes diligence. It takes moral clarity. It takes ingenuity. And above all, it takes a willingness to try."

- Atul Gawande
Acknowledgements

• Center for Clinical Epi:
  – Robert Gross, MD, MSCE
  – Russell Localio, PhD
  – Valerie Teal, MS

• Infectious Diseases:
  – Valerianna Amorosa, MD
  – Jay Kostman, MD

• Gastroenterology:
  – David E. Kaplan, MD
  – Rose O’Flynn, PharmD

• Funding Sources:
  – K01 AI07001
  – VA Pilot Project Grant

• Patients in VA Hepatitis C Case Registry